Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst
Portfolio Pulse from Vandana Singh
Cantor Fitzgerald has initiated coverage of Atossa Therapeutics Inc (NASDAQ:ATOS) with an Overweight rating and a price target of $5. The analysts believe that the market has underappreciated the potential of ATOS' lead program (Z)-endoxifen, a promising new selective estrogen receptor modulator (SERM) for breast cancer treatment. They expect positive data readouts to drive upward earnings estimate revisions and ATOS' stock higher.
September 08, 2023 | 6:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics' stock may rise in the short term due to Cantor Fitzgerald's Overweight rating and $5 price target. The potential of its lead program (Z)-endoxifen is seen as underappreciated.
The Overweight rating and $5 price target given by Cantor Fitzgerald indicate a positive outlook for Atossa Therapeutics. The analysts' belief that the market has underappreciated the potential of ATOS' lead program (Z)-endoxifen suggests that there may be a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100